Recombinant-attenuated Salmonella vaccines modified to reduce virulence. (Q50035660)

23 February 2018

title

Recombinant-attenuated Salmonella vaccines modified to reduce virulence. (English)

1 reference

23 February 2018

1 reference

Lauren Constable

1

1 reference

23 February 2018

publication date

1 August 2011

1 reference

23 February 2018

Expert Review of Vaccines

published in

1 reference

23 February 2018

volume

10

1 reference

23 February 2018

issue

8

1 reference

23 February 2018

page(s)

1117

1 reference

23 February 2018

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

cites work

1 reference

A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers

21 January 2018

1 reference

Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine

21 January 2018

1 reference

Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers

21 January 2018

1 reference

Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1

21 January 2018

1 reference

A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120.

21 January 2018

1 reference

Structural and immunogenicity studies of a cleaved, stabilized envelope trimer derived from subtype A HIV-1

21 January 2018

1 reference

The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region

21 January 2018

1 reference

Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region

21 January 2018

1 reference

Priming B cell-mediated anti-HIV envelope responses by vaccination allows for the long-term control of infection in macaques exposed to a R5-tropic SHIV.

21 January 2018

1 reference

Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterolo

21 January 2018

1 reference

Immunization with HIV-1 SF162-derived Envelope gp140 proteins does not protect macaques from heterologous simian-human immunodeficiency virus SHIV89.6P infection

21 January 2018

1 reference

Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge

21 January 2018

1 reference

HIV vaccine design and the neutralizing antibody problem

21 January 2018

1 reference

Generation and structural analysis of soluble oligomeric gp140 envelope proteins derived from neutralization-resistant and neutralization-susceptible primary HIV type 1 isolates

21 January 2018

1 reference

Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1.

21 January 2018

1 reference

A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure

21 January 2018

1 reference

Effects of HIV Type 1 Envelope Glycoprotein Proteolytic Processing on Antigenicity

21 January 2018

1 reference

Selective recognition of oligomeric HIV-1 primary isolate envelope glycoproteins by potently neutralizing ligands requires efficient precursor cleavage.

21 January 2018

1 reference

Biochemical and biophysical comparison of cleaved and uncleaved soluble, trimeric HIV-1 envelope glycoproteins

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERV.11.97

1 reference

23 February 2018

PubMed ID

21961199

1 reference

23 February 2018